Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA 'ecstasy')

Drug Safety

Volumn 15, Issue 2, 1996, Pages 107-115

  McCann, Una D ^a   Slate, Shiyoko O ^a   Ricaurte, George A ^b,c  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE;

ANOREXIA; BRUXISM; CORNEA EROSION; DIAPHORESIS; DRUG TOXICITY; HALLUCINATION; HEADACHE; HEART PALPITATION; HOT FLUSH; HUMAN; HYPERREFLEXIA; HYPERTENSION; INSOMNIA; MENTAL DISEASE; MICTURITION DISORDER; MUSCLE TONE; MYALGIA; NAUSEA; NEUROTOXICITY; NONHUMAN; NYSTAGMUS; PARESTHESIA; PRIORITY JOURNAL; RESPIRATION DEPRESSION; REVIEW; SEROTONINERGIC NERVE CELL; SYNCOPE; TIC; TRISMUS; VISUAL HALLUCINATION; VISUAL IMPAIRMENT; VOMITING; WALKING; XEROSTOMIA;

EID: 0029846728     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199615020-00003     Document Type: Review

References (88)

1. Shulgin AT, Nichols DE. Characterization of three new psychotomimetics. In: Stillman R, Willette R, editors. The psychopharmacology of hallucinogens. New York: Pergamon Press, 1978: 74-83
2. Greer G. Using MDMA in psychotherapy. Advances 1985; 2 (2): 57
3. Greer G, Strassman RJ. Information on ecstasy [letter]. Am J Psychiatry 1985; 142: 1391
4. Lawn JC. Schedules of controlled substances; temporary placement of 3,4-methylenedioxymethamphetamine. J Pharm Exp Ther 1987; 240: 1-7
5. Ricaurte G, Bryan G, Strauss L, et al. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 1985; 229: 986-8
6. Abbot A, Concar D. A trip into the unknown. New Sci 1992; 29: 30-4
7. Randall T. (1992) Ecstasy-fueled 'rave' parties become dances of death for English youths. JAMA 1992; 268 (12): 1505-6
8. Schmidt CJ. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharm Exp Ther 1987; 240: 1-7
9. Commins DL, Vosmer G, Virus R, et al. Biochemical and histological evidence that methylenedioxymethamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 1987; 241: 338-45
10. O'Hearn EG, Battaglia G, De Souza, et al. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence. J Neurosci 1988; 8: 2788-803
11. 3H]paroxetine-labelled serotonin uptake sites. J Pharmacol Exp Ther 1987; 242 (3): 911-6
12. Stone DM, Stahl DS, Hanson GL, et al. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine on monoaminergic systems in the rat brain. Eur J Pharmacol 1986; 128: 41-8
13. Slikker W, Ali SF, Scallet C, et al. Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). Toxicol Appl Pharmacol 1988; 94: 448-57
14. Slikker Jr W, Holson RR, Ali SF, et al. Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate. Neurotoxicology 1989; 10 (3): 529-49
15. Ricaurte GA, Forno LS, Wilson MA, et al. (+)3,4-methylenedioxymethamphetamine (MDMA) selectively damaged central serotonergic neurons in non human primates. JAMA 1988; 260 (1): 51-5
16. Insel T, Battaglia G, Johannessen J, et al. 3,4-methylenedioxymethamphetamine ('Ecstasy') selectively destroys brain serotonin terminals in rhesus monkeys. J Pharm Exp Ther 1989; 249 (3): 713-20
17. Molliver ME, Berger UV, Mamounas LA, et al. Neurotoxicity of MDMA and related compounds: anatomic studies. Ann NY Acad Sci 1990; 600: 640-64
18. Wilson MA, Ricaurte GA, Molliver ME. Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to MDMA. Neuroscience 1989; 28: 121-37
19. Ricaurte GA, Katz JL, Martello MB. Lasting effects of (±)3,4-methylenedioxymethamphetamine on central serotonergic neurons in non-human primates. J Pharmacol Exp Ther 1992; 261 (2): 616-22
20. Ricaurte GA, DeLanney LE, Irwin I, et al. Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res 1988; 446: 165-8
21. McCann UD, Ricaurte GA. Strategies for detecting partial monoamine depletions in humans. Natl Inst Drug Abuse Res Monogr Ser 1993; 136: 35-52
22. McCann UD, Ridenour A, Shaham Y, et al. Brain serotonergic neurotoxicity after MDMA ('ecstasy'): a controlled study in humans. Neuropsychopharmacology 1994; 10: 129-38
23. Seymour RB. MDMA. San Francisco: Haight Ashhury Publications, 1986
24. Downing J. The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 1986; 18: 335-40
25. Greer G, Tolbert P. Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 1986; 18: 319-27
26. Peroutka SJ, Newman H, Harris H. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1988; 1 (4): 273-7
27. Leister MB, Grob CS, Bravo GL, et al. Phenomenology and sequelae of 3,4-Methylenedioxymethamphetamine use. J Nerv Ment Dis 1992; 180: 345-52
28. Solowij N, Hall W, Lee N. Recreational MDMA use in Sydney: a profile of 'ecstasy' users and their experiences with the drug. Br J Addict 1992; 87: 1161-72
29. O'Neill D, Dan J. Methylenedioxymethamphetamine ('Ecstasy') associated keratopathy. Eye 1993; 7: 805-6
30. Bryden AA, Rothwell PJN, O'Reilly PH. Urinary retention with misuse of 'Ecstasy' [letter]. BMJ 1995; 310: 504
31. Levine AJ, Drew S, Rees GM. 'Ecstasy' induced pneumomediastinum. J R Soc Med 1993; 86: 232-3
32. Rittoo D, Rittoo DB, Rittoo D. Misuse of ecstasy [letter]. BMJ 1992; 305: 309
33. Satchell SC, Connaughton M. Inappropriate hormone secretion and extreme rises in serum creatinine kinase following MDMA ingestion. BMJ 1994; 51 (9): 495
34. Maxwell DL, Polkey MI, Henry JA. Hyponatraemia and catatonic stupor after taking 'ecstasy'. BMJ 1993; 27: 1399
35. Russell ARB, Schwartz RH, Dawling S. Accidental ingestion of 'ecstasy' (3,4-methylenedioxymethamphetamine). Arch Dis Child 1992; 67: 1114-5
36. Dowling GP, McDonough ET, Bost RO. 'Eve' and 'ecstasy': a report of five deaths associated with the use of MDA and MDMA. JAMA 1987; 257 (12): 1615-7
37. Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ('ecstasy'). Lancet 1992; 340: 384-7
38. Suarez RV, Riemersma R. 'Ecstasy' and sudden cardiac death. Am J Forensic Med Path 1988; 9 (4): 339-41
39. Gledhill JA, Moore DF, Bell D, et al. Subarachnoid hemorrhage associated with MDMA abuse. J Neurol Neurosurg Psych 1993; 56 (9): 1036-7
40. Hughes JC, McCabe M, Evans RJ. Intracranial haemorrhage associated with ingestion of 'ecstasy'. Arch Emerg Med 1993; 10: 372-4
41. Manchanda S, Connolly MJ. Cerebral infarction in association with ecstasy abuse. Postgrad Med J 1993; 69: 874-5
42. Selmi F, Davies KG, Sharma RR, et al. Intracerebral hemorrhage due to amphetamine abuse: report of two cases with underlying arteriovenous malformations. Br J Neurosurg 1995; 9: 93-6
43. Harries DP, De Silva R. 'Ecstasy' and intracerebral haemorrhage [letter]. Scott Med 1992; 37 (5): 476
44. Hanyu S, Ikeguchi K, Imai H, et al. Cerebral infarction associated with 3,4-methylenedioxymethamphetamine ('ecstasy') abuse [letter]. Eur Neurol 1995; 35: 173
45. Rothwell PM, Grant R. Cerebral venous sinus thrombosis induced by 'ecstasy' [letter]. J Neurol Neurosci Psychiatry 1993; 56: 1085-9
46. Squier MV, Jalloh S, Hilton-Jones D, et al. Death after ecstasy ingestion: neuropathological findings [letter]. J Neurol Neurosurg Psychiatry 1995; 58: 756
47. Brown C, Osterloh J. Multiple complications from recreational ingestion of MDMA ('Ecstasy'). JAMA 1987; 258: 780-1
48. Chadwick IS, Linsley A, Freemont AJ, et al. Ecstasy, 3-4 methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia [letter]. J R Soc Med 1991; 84: 371
49. Campkin NTA, Davies UM. Another death from ecstasy [letter]. J R Soc Med 1992; 85: 61
50. Screaton GR, Cairns HS, Sarner M, et al. Hyperpyrexia and rhabdomyolysis aller MDMA ('ecstasy') abuse [letter]. Lancet 1992; 339 (8794): 677-8
51. Henry J. Ecstasy and the dance of death. BMJ 1992; 305: 5-6
52. Barrett PJ, Taylor GT. 'Ecstasy' ingestion: a case report of severe complications. J R Soc Med 1993; 86: 233-4
53. Padkin A. Treating MDMA ('Ecstasy') [letter]. Anesthesia 1994; 49 (3): 259
54. Wake D. Ecstasy overdose: a case study. Intens Crit Care Nurs 1995; 11 (1): 6-9
55. Walsh T, Carmichael R, Chestnut R. A hyperthermic reaction to 'ecstasy' [letter]. Br J Hosp Med 1994; 51 (4): 476
56. Roberts L, Wright H. Survival following intentional massive overdose of 'ecstasy'. J Accid Emerg Med 1993; 11: 53-4
57. Lehmann ED, Thorn CH, Croft DN. Delayed severe rhabdomyolysis after taking ecstasy [letter]. Postgrad Med J 1995; 71: 186-7
58. Whitaker-Azmitia PM, Aronson TA. 'Ecstasy' (MDMA)-induced pain [letter]. Am J Psychiatry 1989; 146 (1): 119
59. McCann UD, Ricaurte GA. MDMA ('ecstasy') and panic disorder: induction by a single dose. Biol Psychiatry 1992; 32: 950-3
60. Pallanti S, Mazzi D. MDMA (ecstasy) precipitation of panic-disorder. Biol Psychiatry 1992; 32: 91-5
61. Cox DE. 'Rave' to the grave. Forensic Sci Int 1993; 60: 5-6
62. Creighton FJ, Black DL, Hyde CE. 'Ecstasy' psychosis and flashbacks. Br J Psychiatry 1991; 159: 713-5
63. Williams H, Meagher D, Galligan P. MDMA ('ecstasy'): a case of possible drug-induced psychosis. Irish J Med Sci 1993; 162 (2): 43-4
64. Cadier M, Clarke J. Ecstasy and Whizz at a rave resulting in a major burn plus complications. Burn 1993; 19 (3): 239-40
65. Houft PJ, Van de Voorde HP. Reckless behaviour related to the use of 3,4 methylenedioxymethamphetamine (ecstasy): apropos of fatal accident during car-surfing. Int J Legal Med 1994; 106: 328-9
66. Schifano F. Dangerous driving and MDMA (ecstasy) abuse. J Serotonin Res 1995; 1: 53-7
67. Duxbury AJ. Ecstasy denial implications (letter). Br Dent J 1993; 175 (1): 38
68. Smilkstein M, Smolinske SC, Rumack BH. A case MAO inhibitor/MDMA: agony after ecstasy. Clin Toxicol 1987; 25: 149-59
69. Marsh J, Abhoudi Z, Gibson E, et al. A plastic anaemic following exposure to methylenedioxymethamphetamine ('Ecstasy'). Br J Haematol 1994; 88: 281-5
70. Shearman JD, Satsangi J, Chapman RWG, et al. Misuse of ecstasy [letter]. BMJ 1992; 305: 309
71. Ijzermans JNM, Tilanus HW, De Man RA et al. Ecstasy and liver transplantation [letter]. Ann Med Interne (Paris) 1993; 144 (8): 568
72. Oranje WA, von Pol P, van der Wurff A, et al. XTC-induced hepatitis. Neth J Med 1994; 44: 56-9
73. Dykhuizen RS, Brunt PW, Atkinson P, et al. Ecstasy induced hepatitis mimicking viral hepatitis. Gut 1995; 36 (6): 939-41
74. Series H, Boeles S, Dorkins E, et al. Psychiatric complications of 'ecstasy' use. J Psychopharmacol 1994; 8 (1): 60-1
75. Schifano F, Magni G. MDMA ('ecstasy') abuse: psychopathological features and craving for chocolate - a case series. Soc Biol Psychiatry 1994; 36: 763-7
76. Mcguire PK, Cope H, Fahy T. Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine ('ecstasy'). Br J Psychiatry 1994; 165 (3): 391-5
77. McGuire P, Fahy T. Chronic paranoid psychosis after misuse of MDMA ('ecstasy'). BMJ 1991; 302: 607
78. Schifano F. Chronic atypical psychosis associated with MDMA ('ecstasy') abuse [letter]. Lancet 1991; 338: 1335
79. Wodarz N, Boning J. 'Ecstasy' induziertes psychotisches Depersonalisationssyndrom. Nervenarzt 1993; 64: 478-80
80. McCann UD, Ricaurte GA. Lasting neuropsychiatric sequelae of (±) methylenedioxymethamphetamine ('ecstasy') in recreational users. J Clin Psychopharmacol 1991; 11: 302-5
81. Benazzi F, Mazzoli M. Psychiatric illness associated with 'ecstasy' [letter]. Lancet 1991; 338: 1520
82. O'Callahan J, Miller D. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 1994; 270(2): 741-51
83. Miller DB, O'Callaghan JP. Environment-, drug-, and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 1994; 270 (2): 752-60
84. Ricaurte GA, McCann UD. Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann NY Acad Sci 1992; 648: 371-82
85. Ricaurte GA, Finnegan KT, Irwin I, et al. Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations. Ann NY Acad Sci 1990; 600: 699-710
86. Peroutka SJ, Pascoe N, Faull KF. Monoamine metabolites in the CSF of recreational users of 3,4-methylenedioxymethamphetamine (MDMA; 'Ecstasy'). Res Comm Substance Abuse 1987; 8: 125-38
87. Ricaurte GA, Delanney LE, Wiener SG, et al. 5-Hydroxy-indoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates. Brain Res 1988; 474: 359-63
88. Allen RP, McCann, UD, Ricaurte GA. Persistent effects of (+) 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on human sleep. Sleep 1993; 16 (6): 560-4